Citation:Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, et al 2013

From Cancer Guidelines Wiki

Citation


Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol 2013 Sep;14(10):981-8 Available from: http://www.ncbi.nlm.nih.gov/pubmed/23883922.



Critical appraisals

Critical appraisal linkClinical questionAssigned toStatus
Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, et al 2013What is the optimal systemic therapy regimen for patients with poor performance status for treatment of stage IV inoperable NSCLC?Assoc. Prof. Nick Pavlakiscompleted
Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, et al 2013 2Which new agent or platinum combination regimen is best for treatment of stage IV inoperable NSCLC?Assoc. Prof. Nick Pavlakiscompleted
Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, et al 2013 3Is monotherapy with new third generation (3G) agents as effective as platinum combination therapy for treatment of stage IV inoperable NSCLC?Assoc. Prof. Nick Pavlakiscompleted
Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, et al 2013 4What is the optimal systemic therapy regimen for patients with oncogenic driver mutations (including EGFR and ALK)?Assoc. Prof. Nick Pavlakiscompleted

Compare quality appraisals for each clinical question

  • [[Clinical question:What is the optimal systemic therapy regimen for patients with poor performance status for treatment of stage IV inoperable NSCLC?|
    Invalid title «<span class="smw-format list-format "><span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:What is the optimal systemic therapy regimen for patients with poor performance status for treatment of stage IV inoperable NSCLC?</span></span></span>»
    ]] (compare critical appraisals)
  • [[Clinical question:Which new agent or platinum combination regimen is best for treatment of stage IV inoperable NSCLC?|
    Invalid title «<span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:Which new agent or platinum combination regimen is best for treatment of stage IV inoperable NSCLC?</span></span></span>»
    ]] (compare critical appraisals)
  • [[Clinical question:Is monotherapy with new third generation (3G) agents as effective as platinum combination therapy for treatment of stage IV inoperable NSCLC?|
    Invalid title «<span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:Is monotherapy with new third generation (3G) agents as effective as platinum combination therapy for treatment of stage IV inoperable NSCLC?</span></span></span>»
    ]] (compare critical appraisals)
  • [[Clinical question:What is the optimal systemic therapy regimen in selected patients for treatment of stage IV inoperable NSCLC?|
    Invalid title «<span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:What is the optimal systemic therapy regimen in selected patients for treatment of stage IV inoperable NSCLC?</span></span></span></span>»
    ]] (compare critical appraisals)

Cited by

  1. What is the optimal second-line therapy in patients with stage IV inoperable NSCLC?
Retrieved from "https://wiki.cancer.org.au/australiawiki/index.php?title=Citation:Garassino_MC,_Martelli_O,_Broggini_M,_Farina_G,_Veronese_S,_Rulli_E,_et_al_2013&oldid=68626"